BriaCell Therapeutics (NASDAQ:BCTX) Stock Price Up 5.4% – Still a Buy?

BriaCell Therapeutics Corp. (NASDAQ:BCTX) rose 5.4% during trading on Wednesday . The company traded as high as $0.62 and last traded at $0.60. Approximately 623,193 shares traded hands during trading, a decline of 60% from the average daily volume of 1,563,530 shares. The stock had previously closed at $0.57.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of BriaCell Therapeutics in a research note on Thursday, October 3rd.

BriaCell Therapeutics Stock Down 7.5 %

The company has a market capitalization of $26.40 million, a P/E ratio of -0.67 and a beta of 1.39. The company’s 50-day moving average is $0.78 and its two-hundred day moving average is $0.98.

BriaCell Therapeutics (NASDAQ:BCTX) last released its earnings results on Monday, October 28th. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.45. On average, sell-side analysts predict that BriaCell Therapeutics Corp. will post -0.58 EPS for the current year.

Institutional Trading of BriaCell Therapeutics

A hedge fund recently bought a new stake in BriaCell Therapeutics stock. Vontobel Holding Ltd. purchased a new position in BriaCell Therapeutics Corp. (NASDAQ:BCTX) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 80,000 shares of the company’s stock, valued at approximately $99,000. Vontobel Holding Ltd. owned 0.44% of BriaCell Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 15.42% of the company’s stock.

About BriaCell Therapeutics

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.